EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02192515
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 707
- Registration Number
- NCT02175173
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Completed
- Conditions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 1647
- Registration Number
- NCT02175693
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Completed
- Conditions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02175719
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 8662
- Registration Number
- NCT02162264
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 3482
- Registration Number
- NCT02162251
A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02146261
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT02135107
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT02094729
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02094053
© Copyright 2024. All Rights Reserved by MedPath